348 results on '"Meyer T"'
Search Results
2. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
3. FIFA Sudden Death Registry (FIFA SDR): Update from 2014 to April 2023 in Australia and Asia
4. Incidence, characteristics and cost of head, neck and dental injuries in non-professional football using 3 years of sports injury insurance data
5. Hypomagnesemia and Survival in Patients with Cervical Cancer Treated with Definitive Chemoradiotherapy
6. Impact of Immune, Inflammatory, and Nutritional Indices on Outcome in Patients with Cervical Cancer Treated with Definitive (Chemo)radiotherapy
7. LB1776 Optimized culture conditions of hidradenitis suppurativa skin for preclinical screening ex vivo
8. Early stages of corrosion of stainless steel 309 S in geological brines studied by sychrotron radiation photoelectron spectroscopy
9. Fabrication of Bijels with Sub-Micron Domains with a Single-Channel Flow Device
10. LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
11. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
12. EP02.03-023 Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery
13. 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
14. Fabrication of bijels with sub-micron domains via a single-channel flow device
15. Agency and representation in internet governance
16. Analyse der Kontaktzeiten in der Bundesliga während der SARS-CoV-2 Pandemie mittels Tracking Daten
17. Corrigendum to “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
18. Evaluation of a digital food scanner to monitor food intake in a clinical setting
19. P.0837 Xanomeline's activity in rodent models of psychosis: Role of central muscarinic receptors and augmentation by antipsychotic drugs
20. 68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
21. The effect of ball characteristics on head impact magnitude during purposeful heading in adolescent male and female football players
22. The effect of a neuromuscular neck exercise program on head impact magnitude during heading: A pilot randomised controlled trial
23. P02.03 Robotic Bronchoscopy: Navigating the Change in Lung Nodule Management
24. Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA)
25. Erfolgreiches ’Return to Football’ nach Covid-19 Lockdown 2020 – Eine Kohortenstudie zum Hygienekonzept des Deutschen Profifußballs
26. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
27. Keine erhöhte Verletzungsinzidenz in der 1. Fußball-Bundesliga nach dem Re-Start in Folge des SARS-CoV-2 Lockdowns 2020
28. Kontaktzeiten im Profifußball vor der Covid-19-Pandemie – Eine retrospektive Analyse der Trackingdaten von Fußball-Bundesliga-Spielen
29. Surface composition and micromasking effect during the etching of amorphous Ge-Sb-Se thin films in SF6 and SF6/Ar plasmas
30. The rise and fall of executive functions in high-level football players
31. MVA-BN as monkeypox vaccine for healthy and immunocompromised
32. ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up.
33. DMD & BMD – CLINICAL
34. SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo
35. 851 Acetyl zingerone opposes deleterious effects of skin aging by bolstering matrisome synthesis, neutralizing oxidative stress and inhibiting DNA damage
36. Animal Model of Cardiac Reperfusion Injury to Evaluate the Effects of Electrical Microcurrent Application: Preliminary Results
37. Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
38. Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
39. A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
40. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
41. Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
42. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
43. First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC)
44. Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
45. Approaches of Sparing Lung in SBRT for Treating Tumors in Lungs with Volumetric Arc Therapy
46. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
47. Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
48. Correction to: “Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
49. Improvement of Left Ventricular Ejection Fraction by a Novel Electrical Microcurrent Therapy in a Sheep Model of Chronic Heart Failure
50. PO-1049 Assessing PTV margin adequacy in permanent breast seed implant for complex target geometries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.